What lured Hal Bar­ron away?; Top FDA minds on ac­cel­er­at­ed ap­proval re­forms; ‘Dead wrong’ Aduhelm ad blitz; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Noth­ing can re­al­ly com­pete with Hal Bar­ron’s de­par­ture from Glax­o­SmithK­line as the news of the week, but we do have plen­ty of orig­i­nal re­port­ing and analy­sis from the End­points team in this edi­tion. En­joy and have a nice week­end.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER